Concepedia

Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial

Jesús S. Mora, Angela Genge, Adriano Chiò, Conrado J. Estol, Delia Chaverri, Saúl Marín, Javier Mascías, Gabriel Rodríguez, Mónica Povedano, Andrés Paipa,

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2019 · 222 citations · 18 references

DOIFull text

Open access

Concepts

Abstract

Results show that masitinib at 4.5 mg/kg/d can benefit patients with ALS. A confirmatory phase 3 study will be initiated to substantiate these data.

References

18

Comprehensive analysis of kinase inhibitor selectivity

Mindy I. Davis, Jeremy P. Hunt, Sanna Herrgård et al. · Nature Biotechnology · 2011 · 2.4K citations · Full text

, , +14

El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis

Benjamin Rix Brooks · Journal of the Neurological Sciences · 1994 · 2.1K citations

, , +14

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

Koji Abe, Masashi Aoki, Shoji Tsuji et al. · The Lancet Neurology · 2017 · 925 citations

, , +11

Projected increase in amyotrophic lateral sclerosis from 2015 to 2040

Karissa Arthur, Andrea Calvo, T. Ryan Price et al. · Nature Communications · 2016 · 458 citations · Full text

, , +13

Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT

Patrice Dubreuil, Sébastien Letard, Marco A. Ciufolini et al. · PLoS ONE · 2009 · 412 citations · Full text

, , +15